Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ. Bulitta JB, et al. Among authors: awada a. Cancer Chemother Pharmacol. 2009 May;63(6):1049-63. doi: 10.1007/s00280-008-0827-2. Epub 2008 Sep 13. Cancer Chemother Pharmacol. 2009. PMID: 18791718 Clinical Trial.
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ. Bulitta JB, et al. Among authors: awada a. Cancer Chemother Pharmacol. 2009 May;63(6):1035-48. doi: 10.1007/s00280-008-0828-1. Epub 2008 Sep 13. Cancer Chemother Pharmacol. 2009. PMID: 18791717 Clinical Trial.
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, Punt C, Verweij J, van Oosterom A, Morant R, Wanders J, Hanauske AR. Pavlidis N, et al. Among authors: awada a. Cancer Chemother Pharmacol. 2000;46(2):167-71. doi: 10.1007/s002800000134. Cancer Chemother Pharmacol. 2000. PMID: 10972487 Clinical Trial.
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR, Piccart M; European Organization for Research and Treatment of Cancer Early Clinical Studies Group. Eskens FA, et al. Among authors: awada a. J Clin Oncol. 2001 Feb 15;19(4):1167-75. doi: 10.1200/JCO.2001.19.4.1167. J Clin Oncol. 2001. PMID: 11181683 Clinical Trial.
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.
Milojkovic Kerklaan B, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart MJ, Schellens JH, Awada A. Milojkovic Kerklaan B, et al. Among authors: awada a. Cancer Chemother Pharmacol. 2013 Jan;71(1):53-62. doi: 10.1007/s00280-012-1972-1. Epub 2012 Sep 29. Cancer Chemother Pharmacol. 2013. PMID: 23053259 Clinical Trial.
546 results